These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18181014)

  • 41. [Hereditary ovarian cancer].
    Zikán M; Foretová L; Cibula D; Kotlas J; Pohlreich P
    Ceska Gynekol; 2006 May; 71(3):246-51. PubMed ID: 16768054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Guindalini RS; Song A; Fackenthal JD; Olopade OI; Huo D
    Cancer; 2016 Jun; 122(12):1913-20. PubMed ID: 26992017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hereditary breast and ovarian cancer: research on how women respond to genetic testing.
    Bingham R
    Nurs Womens Health; 2012; 16(4):319-24. PubMed ID: 22900808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
    Prucka SK; McIlvried DE; Korf BR
    Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility.
    Alamian A; Rouleau I; Simard J; Dorval M
    Nutr Cancer; 2006; 54(2):157-65. PubMed ID: 16898859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
    Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
    Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
    Dombernowsky SL; Weischer M; Freiberg JJ; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2339-42. PubMed ID: 19661094
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
    Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
    JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognosis of probability of BRCA1 and BRCA2 mutations carriage in women with compromised family history of breast and/or ovarian cancer.
    Rybchenko LA; Bychkova AM; Skyban GV; Klymenko SV
    Probl Radiac Med Radiobiol; 2013; (18):253-60. PubMed ID: 25191729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
    Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.
    Seymour IJ; Casadei S; Zampiga V; Rosato S; Danesi R; Scarpi E; Falcini F; Strada M; Morini N; Naldoni C; Amadori D; Calistri D
    Breast Cancer Res Treat; 2008 Nov; 112(2):343-9. PubMed ID: 18092194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
    Frank TS; Manley SA; Olopade OI; Cummings S; Garber JE; Bernhardt B; Antman K; Russo D; Wood ME; Mullineau L; Isaacs C; Peshkin B; Buys S; Venne V; Rowley PT; Loader S; Offit K; Robson M; Hampel H; Brener D; Winer EP; Clark S; Weber B; Strong LC; Thomas A
    J Clin Oncol; 1998 Jul; 16(7):2417-25. PubMed ID: 9667259
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hereditary ovarian cancer--assessing risk and prevention strategies.
    Pavelka JC; Li AJ; Karlan BY
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacoprevention for hereditary breast and ovarian cancer.
    Cazzaniga M; Bonanni B
    Minerva Ginecol; 2016 Oct; 68(5):517-35. PubMed ID: 26928419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.